Ken Griffin Kura Oncology, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,800 shares of KURA stock, worth $201,782. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,800

Previous 8,200 19.51%

Holding current value

$201,782

Previous $117,000 78.63%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$13.42 - $23.53 $14.8 Million - $25.9 Million	-1,102,125 Reduced 98.35%	18,447 $393,000
Q4 2023 Feb 14, 2024	SELL	$7.58 - $14.38 $2.67 Million - $5.06 Million	-351,720 Reduced 23.89%	1,120,572 $16.1 Million
Q3 2023 Nov 14, 2023	SELL	$8.44 - $11.86 $3.75 Million - $5.27 Million	-444,323 Reduced 23.18%	1,472,292 $13.4 Million
Q2 2023 Aug 14, 2023	SELL	$9.62 - $13.99 $182,703 - $265,698	-18,992 Reduced 0.98%	1,916,615 $20.3 Million
Q1 2023 May 15, 2023	BUY	$10.71 - $14.6 $13 Million - $17.7 Million	1,211,847 Added 167.44%	1,935,607 $23.7 Million

Q4 2022 Feb 14, 2023	BUY	$11.23 - $16.9 $4.73 Million - $7.12 Million	421,594 Added 139.52%	723,760 $8.98 Million
Q3 2022 Nov 14, 2022	BUY	$12.01 - $19.45 $2.33 Million - $3.77 Million	194,032 Added 179.44%	302,166 $4.13 Million
Q2 2022 Aug 15, 2022	SELL	$10.71 - $18.33 $488,365 - $835,829	-45,599 Reduced 29.66%	108,134 $1.98 Million
Q1 2022 May 16, 2022	SELL	$11.78 - $16.98 $1.36 Million - $1.96 Million	-115,417 Reduced 42.88%	153,733 $2.47 Million
Q4 2021 Feb 14, 2022	BUY	$12.22 - $19.57 $1.62 Million - $2.6 Million	132,692 Added 97.24%	269,150 $3.77 Million
Q3 2021 Nov 15, 2021	BUY	$15.42 - $21.72 $1.5 Million - $2.11 Million	96,953 Added 245.42%	136,458 $2.56 Million
Q2 2021 Aug 16, 2021	SELL	$20.85 - $29.88 $29.1 Million - $41.7 Million	-1,395,712 Reduced 97.25%	39,505 $823,000
Q1 2021 May 17, 2021	SELL	$24.75 - $39.14 $40.4 Million - $63.9 Million	-1,632,396 Reduced 53.21%	1,435,217 $40.6 Million
Q4 2020 Feb 16, 2021	BUY	$29.0 - $41.62 $27.2 Million - $39 Million	936,627 Added 43.95%	3,067,613 $100 Million
Q3 2020 Nov 16, 2020	BUY	$16.3 - $30.64 $18.7 Million - $35.2 Million	1,149,804 Added 117.19%	2,130,986 $65.3 Million
Q2 2020 Aug 14, 2020	BUY	$7.95 - $18.81 $2.97 Million - $7.02 Million	373,228 Added 61.39%	981,182 $16 Million
Q1 2020 May 15, 2020	BUY	$6.45 - $14.04 $3.55 Million - $7.72 Million	550,149 Added 951.73%	607,954 $6.05 Million
Q4 2019 Feb 14, 2020	BUY	$12.97 - $15.94 $553,650 - $680,430	42,687 Added 282.36%	57,805 $795,000
Q3 2019 Nov 14, 2019	SELL	$14.75 - $20.87 $4.23 Million - $5.98 Million	-286,568 Reduced 94.99%	15,118 $229,000
Q2 2019 Aug 14, 2019	BUY	$14.71 - $19.79 $3.87 Million - $5.2 Million	262,894 Added 677.7%	301,686 $5.94 Million
Q4 2018 Feb 14, 2019	BUY	$10.6 - $17.49 $116,186 - $191,707	10,961 Added 39.38%	38,792 $544,000
Q3 2018 Nov 13, 2018	BUY	$16.65 - $21.85 $35,347 - $46,387	2,123 Added 8.26%	27,831 $0
Q2 2018 Aug 10, 2018	BUY	$14.8 - $18.8 $380,478 - $483,310	25,708 New	25,708 $0

Others Institutions Holding KURA

# of Institutions

173

Shares Held

80.4M

Call Options Held

914K

Put Options Held

120K

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $1.38B
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account